A Phase III Study Evaluating YL201 Versus ICC in 2L ESCC

Exclusion Criteria

• •1. Other malignancies within 5 years prior to first dose or currently concurrent malignancies.
• •2. Prior treatment-related adverse events not resolved to ≤Grade 1 per CTCAE v5.0, except for alopecia (any grade), hyperpigmentation (any grade), peripheral neuropathy (≤ Grade 2), and lymphopenia (≤ Grade 3).
• •3. Major surgery, significant traumatic injury within 4 weeks prior to first dose, or anticipated need for major surgery during study treatment
• •4. Any arterial thromboembolic event within 6 months prior to randomization, or venous thromboembolic events of Grade ≥ 3 according to NCI CTCAE version 5.0.
• •5. Known active tuberculosis (TB). Participants suspected of having active TB must undergo clinical evaluation to rule it out.
• •6. History of immunodeficiency or positive test for human immunodeficiency virus (HIV) antibodies. Participants with known active syphilis infection are also excluded.
• •7. Current active infection with hepatitis B virus (HBV) or hepatitis C virus (HCV).
• •8. Known allergy to any component of the investigational product; history of severe allergic reactions (e.g., anaphylactic shock); or known history of severe hypersensitivity reactions to other monoclonal antibodies or recombinant proteins, or previous severe infusion reactions.
• •9. Women who are pregnant, breastfeeding, or planning to become pregnant or breastfeed during the study period.
• •10. Any disease, medical condition, organ dysfunction, or social/psychological circumstance that, in the investigator's judgment, may interfere with the participant's ability to sign the informed consent form (ICF), compromise cooperation or compliance with study procedures, or affect the interpretation of study results. This includes, but is not limited to, psychiatric disorders, substance/alcohol abuse, or a history of drug abuse.